BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Criscitiello C, Corti C, Pravettoni G, Curigliano G. Managing side effects of immune checkpoint inhibitors in breast cancer. Crit Rev Oncol Hematol 2021;162:103354. [PMID: 34029683 DOI: 10.1016/j.critrevonc.2021.103354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Kholod O, Basket WI, Mitchem JB, Kaifi JT, Hammer RD, Papageorgiou CN, Shyu C. Immune-Related Gene Signatures to Predict the Effectiveness of Chemoimmunotherapy in Triple-Negative Breast Cancer Using Exploratory Subgroup Discovery. Cancers 2022;14:5806. [DOI: 10.3390/cancers14235806] [Reference Citation Analysis]
2 Jungles KM, Holcomb EA, Pearson AN, Jungles KR, Bishop CR, Pierce LJ, Green MD, Speers CW. Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1022542] [Reference Citation Analysis]
3 Lv W, Tan Y, Zhou X, Zhang Q, Zhang J, Wu Y. Landscape of prognosis and immunotherapy responsiveness under tumor glycosylation-related lncRNA patterns in breast cancer. Front Immunol 2022;13:989928. [DOI: 10.3389/fimmu.2022.989928] [Reference Citation Analysis]
4 Deng H, Wang L, Wang N, Zhang K, Zhao Y, Qiu P, Qi X, Zhang D, Xu F, Liu J. Neoadjuvant Checkpoint Blockade in Combination with Chemotherapy in Patients with Tripe-Negative Breast Cancer: Exploratory Analysis of Real-World, Multicenter Data.. [DOI: 10.21203/rs.3.rs-1941236/v1] [Reference Citation Analysis]
5 Corti C, Venetis K, Sajjadi E, Zattoni L, Curigliano G, Fusco N. CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. Expert Opin Investig Drugs 2022;:1-13. [PMID: 35311430 DOI: 10.1080/13543784.2022.2054326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, Andrè F, Curigliano G. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer 2022;8:23. [PMID: 35181659 DOI: 10.1038/s41523-022-00386-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
7 Corti C, Giachetti PPMB, Eggermont AMM, Delaloge S, Curigliano G. Therapeutic vaccines for breast cancer: Has the time finally come? Eur J Cancer 2022;160:150-74. [PMID: 34823982 DOI: 10.1016/j.ejca.2021.10.027] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
8 Corti C, Nicolò E, Curigliano G. Novel immune targets for the treatment of triple-negative breast cancer. Expert Opin Ther Targets 2021;:1-20. [PMID: 34763593 DOI: 10.1080/14728222.2021.2006187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Nie D, Xue Y, Fang Q, Cheng J, Li B, Wang D, Li C, Gui S, Zhang Y, Zhao P. Immune Checkpoints: Therapeutic Targets for Pituitary Tumors. Dis Markers 2021;2021:5300381. [PMID: 34447484 DOI: 10.1155/2021/5300381] [Reference Citation Analysis]